Evaluation of Solid Tumor Patients Presenting with Denovo Bone Marrow Metastasis

Abstract

Aim: Although solid tumors are known to metastasize to the bone marrow, it is rare to be diagnosed with
 bone marrow involvement. In our study, we aimed to contribute to the literature by evaluating the treatment
 results and follow-up processes of different solid tumors metastatic to bone marrow in denovo.
 Material and Methods: We retrospectively analyzed 28 patients who underwent bone marrow biopsy
 with a prediagnosis of hematologic malignancy and were diagnosed with carcinoma metastasis.
 Clinicopathologic features, antitumor treatments, treatment-related hematologic toxicities and factors
 affecting survival were evaluated.
 Results: Of the 28 patients included in the study, 14 (50.0%) were female and 14 (50.0%) were male.
 The median age of the patients was 62 years (28-82). Eight patients (28.6%) were diagnosed with
 breast (28.6%), six with gastric (21.4%), four with lung (14.3%), two each with colon and prostate ca
 (7.1%), and the primary tumor site could not be determined in six patients (21.4%). Progression was
 observed in four (40.0%) of the 10 patients with the first series of treatment, three (30.0%) patients had
 stable response and three (30.0%) patients had partial response. The median progression-free survival
 time was 130 days (3-494 days) in patients who received first line treatment. The median overall survival
 time was 26 days (0-1183 days). Thrombocytopenia (p